BlossomHill gets another $84M for macrocyclic approach to EGFR

With two cancer drugs in clinical testing, BlossomHill Therapeutics has convinced investors to fuel the San Diego startup with another $84 million in its attempt to take on AstraZeneca’s EGFR inhibitor Tagrisso.

CEO Jean Cui …

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registeration number 16808844